Rankings
▼
Calendar
DNLI Q1 2018 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q1 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$641,000
Gross Profit
$641,000
100.0% margin
Operating Income
-$26M
-4016.8% margin
Net Income
-$24M
-3693.9% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
$34M
Free Cash Flow
$33M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$614M
Total Liabilities
$75M
Stockholders' Equity
$539M
Cash & Equivalents
$44M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$641,000
$0
—
Gross Profit
$641,000
$0
—
Operating Income
-$26M
-$22M
-18.4%
Net Income
-$24M
-$21M
-11.1%
← FY 2018
All Quarters
Q2 2018 →